Atossa Therapeutics, Inc. (ATOS)
- Previous Close
1.4200 - Open
1.4100 - Bid 1.4700 x 800
- Ask 1.5000 x 1600
- Day's Range
1.4100 - 1.5100 - 52 Week Range
0.5900 - 2.3100 - Volume
1,161,915 - Avg. Volume
1,640,885 - Market Cap (intraday)
186.703M - Beta (5Y Monthly) 1.24
- PE Ratio (TTM)
-- - EPS (TTM)
-0.2400 - Earnings Date May 13, 2024 - May 17, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
4.58
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.
www.atossatherapeutics.comRecent News: ATOS
Performance Overview: ATOS
Trailing total returns as of 4/23/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ATOS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ATOS
Valuation Measures
Market Cap
176.68M
Enterprise Value
88.22M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
1.94
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-2.81
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-17.84%
Return on Equity (ttm)
-28.80%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-30.09M
Diluted EPS (ttm)
-0.2400
Balance Sheet and Cash Flow
Total Cash (mrq)
88.46M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-11.76M